Nothing Special   »   [go: up one dir, main page]

AR021995A1 - Derivados de quinolina 1,2-anelados. - Google Patents

Derivados de quinolina 1,2-anelados.

Info

Publication number
AR021995A1
AR021995A1 ARP990106687A ARP990106687A AR021995A1 AR 021995 A1 AR021995 A1 AR 021995A1 AR P990106687 A ARP990106687 A AR P990106687A AR P990106687 A ARP990106687 A AR P990106687A AR 021995 A1 AR021995 A1 AR 021995A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkyloxy
alkyloxycarbonyl
aryl
mono
Prior art date
Application number
ARP990106687A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR021995A1 publication Critical patent/AR021995A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

Se relaciona con compuestos de formula (1), las sales de adicion de ácido farmacéuticamente aceptables y las formas estereoquímicamente isoméricas de losmismos, en donde: =X1-X2-X3- es un radical trivalente; >Y1-Y2- es un radical trivalente; r y sso n cada uno independientemente 0 a 5; t es de 0 a 3; cada R1 yR2 son independientemente hidroxi, halo, ciano, alquilo C1-6, trihalometilo, trihalometoxi, alquenilo C2-6, alquiloxi C1-6, hidroxialquiloxi C1-6, alquiltioC1-6, alquiloxi C1-6-alquiloxi C1 -6, alquiloxicarbonilo C1-6, aminoalquiloxi C1-6, mono- o di(alquilo C1-6)amino, mono- o di(alquilo C1-6)aminoalquiloxi C1-6,arilo, arilalquilo C1-6, ariloxi o arilalquiloxi C1-6, hidroxicarbonilo, alquiloxicarbonilo C1-6 o dos R1 o R2en posiciones adyacentes forman juntos unradical bivalente; R3 es hidrogeno, halo, alquilo C1-6, ciano, haloalquilo C1-6, hidroxialquilo C1-6, cianoalquilo C1-6, aminoalquilo C1-6,alquiloxi C1-6-alquilo C1-6, alquiltio C1-6-alquilo C1-6,aminocarbonilalquilo C1-6, hidroxicarbonilo, hidroxicarbonilalquilo C1-6, alquiloxicarbonil C1-6-alquilo C1-6, alquilcarbonil C1-6-alquilo C1-6, alquiloxicarbonilo C1-6, arilo, arilalquiloxi C1-6-alquilo C1-6, mono- o di(alquilo C1-6)aminoalquilo C1- 6; oun radical de formula -O-R10, -S-R10, o -NR11R12; R4 es un imidazolilo opcionalmente sustituido; arilo es un naftalenilo o fenilo opcionalmente sustituido; quetienen actividad inhibitoria de transferasa de geranilgeranilo y transferasa defarnesilo; su preparacion, compos iciones que los contienen y su uso como unamedicina.
ARP990106687A 1998-12-23 1999-12-22 Derivados de quinolina 1,2-anelados. AR021995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98204444 1998-12-23

Publications (1)

Publication Number Publication Date
AR021995A1 true AR021995A1 (es) 2002-09-04

Family

ID=8234557

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106687A AR021995A1 (es) 1998-12-23 1999-12-22 Derivados de quinolina 1,2-anelados.

Country Status (32)

Country Link
US (2) US6458800B1 (es)
EP (1) EP1140935B1 (es)
JP (1) JP4725940B2 (es)
KR (2) KR100818541B1 (es)
CN (1) CN1178938C (es)
AR (1) AR021995A1 (es)
AT (1) ATE240327T1 (es)
AU (1) AU765437B2 (es)
BG (1) BG65124B1 (es)
BR (1) BR9916827A (es)
CA (1) CA2355717C (es)
CZ (1) CZ302374B6 (es)
DE (1) DE69907964T2 (es)
DK (1) DK1140935T3 (es)
EA (1) EA004542B1 (es)
EE (1) EE04962B1 (es)
ES (1) ES2200591T3 (es)
HK (1) HK1038746B (es)
HR (1) HRP20010454B1 (es)
HU (1) HU229404B1 (es)
ID (1) ID29241A (es)
IL (2) IL143859A0 (es)
NO (1) NO318922B1 (es)
PL (1) PL199080B1 (es)
PT (1) PT1140935E (es)
SI (1) SI1140935T1 (es)
SK (1) SK286072B6 (es)
TR (1) TR200101961T2 (es)
TW (1) TW531533B (es)
UA (1) UA71592C2 (es)
WO (1) WO2000039082A2 (es)
ZA (1) ZA200105136B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
JP2003525252A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001244167A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EP1263437A2 (en) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001246478A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
US20030125326A1 (en) * 2000-02-29 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
JP2003525246A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
EP1261341A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU2001293829A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
EP1322644A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ES2313991T3 (es) * 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
AU2001293826A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
IL155163A0 (en) * 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
JP4231691B2 (ja) * 2000-11-28 2009-03-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 炎症性腸疾患の治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
WO2002051835A1 (en) 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US20040110769A1 (en) * 2001-02-15 2004-06-10 End David William Farnesyl protein transferase inhibitor combinations with antiestrogen agents
JP2004526776A (ja) * 2001-04-25 2004-09-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 悪液質を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US7084156B2 (en) * 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
ATE425978T1 (de) 2001-12-19 2009-04-15 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
ES2287466T3 (es) 2002-03-22 2007-12-16 Janssen Pharmaceutica N.V. Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
CA2479109C (en) * 2002-03-29 2011-08-02 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
EP1497295B1 (en) 2002-04-15 2006-08-16 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
JP2007506788A (ja) 2003-09-26 2007-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染阻害剤とその使用法
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
ES2522830T3 (es) 2004-11-05 2014-11-18 Janssen Pharmaceutica N.V. Métodos de control de la eficacia de los inhibidores de la farnesiltransferasa
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
DE102006012545A1 (de) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
NZ572072A (en) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US8343996B2 (en) 2008-11-13 2013-01-01 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
EP2814814B1 (en) * 2012-02-13 2019-05-08 F.Hoffmann-La Roche Ag Imidazolylketone derivatives asd aldosterone synthase inhibitors
AU2013299922B2 (en) 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
JP6251277B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−ガンマ−ｔのフェニル結合キノリニルモジュレーター
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
ES2632269T3 (es) 2012-10-16 2017-09-12 Janssen Pharmaceutica Nv Moduladores de quinolinailo enlazados a metileno de ROR-gamma-t
CN105873439A (zh) 2013-10-15 2016-08-17 詹森药业有限公司 RORγt的烷基连接的喹啉基调节剂
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3285768B1 (en) 2015-04-21 2020-12-30 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
RS62709B1 (sr) 2015-08-17 2022-01-31 Kura Oncology Inc Postupci za lečenje pacijenata obolelih od kancera pomoću inhibitora farneziltransferaze
CN109071425B (zh) * 2016-03-23 2021-01-15 陈裕仁 法尼基转移酶抑制剂及其用途
RS61745B1 (sr) 2016-11-03 2021-05-31 Kura Oncology Inc Inhibitori farneziltransferaze za upotrebu u tretiranju kancera

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
ES2260156T3 (es) 1995-12-08 2006-11-01 Janssen Pharmaceutica N.V. Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de la proteina farnesil-transferasa.
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
HUP0001122A3 (en) * 1997-04-25 2002-03-28 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
RU2209066C2 (ru) * 1997-06-02 2003-07-27 Янссен Фармацевтика Н.В. Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы

Also Published As

Publication number Publication date
CA2355717A1 (en) 2000-07-06
US6914066B2 (en) 2005-07-05
EE04962B1 (et) 2008-02-15
UA71592C2 (uk) 2004-12-15
ES2200591T3 (es) 2004-03-01
CN1331693A (zh) 2002-01-16
PT1140935E (pt) 2003-10-31
KR20010087396A (ko) 2001-09-15
JP2002533435A (ja) 2002-10-08
SK8732001A3 (en) 2002-02-05
BR9916827A (pt) 2001-10-16
TW531533B (en) 2003-05-11
CN1178938C (zh) 2004-12-08
SI1140935T1 (en) 2003-10-31
WO2000039082A3 (en) 2000-10-26
BG65124B1 (bg) 2007-03-30
ID29241A (id) 2001-08-16
KR100712226B1 (ko) 2007-04-27
TR200101961T2 (tr) 2001-12-21
IL143859A0 (en) 2002-04-21
KR20060117380A (ko) 2006-11-16
HRP20010454A2 (en) 2002-06-30
HU229404B1 (en) 2013-12-30
SK286072B6 (sk) 2008-02-05
US20030119843A1 (en) 2003-06-26
AU765437B2 (en) 2003-09-18
BG105631A (en) 2002-02-28
EA200100708A1 (ru) 2001-12-24
JP4725940B2 (ja) 2011-07-13
ATE240327T1 (de) 2003-05-15
EE200100318A (et) 2002-10-15
DK1140935T3 (da) 2003-09-01
CZ20012142A3 (cs) 2002-01-16
PL199080B1 (pl) 2008-08-29
HRP20010454B1 (en) 2004-06-30
CZ302374B6 (cs) 2011-04-20
CA2355717C (en) 2011-02-08
KR100818541B1 (ko) 2008-04-02
NO20013088L (no) 2001-06-21
EP1140935B1 (en) 2003-05-14
HUP0104582A2 (hu) 2002-04-29
ZA200105136B (en) 2002-06-21
AU2795300A (en) 2000-07-31
PL349504A1 (en) 2002-07-29
DE69907964T2 (de) 2004-02-19
HK1038746A1 (en) 2002-03-28
NO20013088D0 (no) 2001-06-21
HK1038746B (zh) 2003-09-05
IL143859A (en) 2008-04-13
EP1140935A2 (en) 2001-10-10
US6458800B1 (en) 2002-10-01
EA004542B1 (ru) 2004-06-24
HUP0104582A3 (en) 2002-12-28
WO2000039082A2 (en) 2000-07-06
NO318922B1 (no) 2005-05-23
DE69907964D1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
AR021995A1 (es) Derivados de quinolina 1,2-anelados.
TW349948B (en) Farnesyl transferase inhibiting 2-quinolone derivatives
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
HUP0301431A2 (hu) 3-Indolil-4-fenil-1H-pirrol-2,5-dion-származékok, mint glikogén szintáz kináz-3béta inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
ES2140961T3 (es) Nuevos derivados de 19-nor-pregneno.
NZ231188A (en) Piperidylthieno triazolodiazepine derivatives and pharmaceutical compositions
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
DE60117847D1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
AP1555A (en) Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance
ATE61347T1 (de) Zytoprotektive derivate zur anwendung bei ischaemischen erkrankungen, ihre herstellung und sie enthaltende zusammensetzungen.
ES2000481A6 (es) Procecimiento de preparacion de nuevos derivados del dihidro-2,3 benzofurano
HUP0303279A2 (hu) Indolo-pirrolo-karbazolok cukorszármazékai, mint topoizomeráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
CA2289787A1 (en) Fungicidal mixtures
CO5580721A2 (es) Composicion fungicida basada en al menos un derivado de piridilmetilbenzamida y al menos un derivado de ditiocarbamato
TW350838B (en) Quinoline derivatives
ES2172294T3 (es) Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
DK0514942T3 (da) Hidtil ukendte benzopyranderivater og fremgangsmåder til fremstilling deraf
DE3769284D1 (de) Fungizide cyclohexylamine.
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
AR027035A1 (es) Pirroles sustituidos
DE60119383D1 (de) Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
AR015130A1 (es) 1,3-dioxolanos 2,4,4-trisubstituidos antimicoticos, su uso para la manufactura de medicamentos, composiciones farmaceuticas que los contienen y procedimiento para preparar estos compuestos.

Legal Events

Date Code Title Description
FG Grant, registration